Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Gilead, BMS Expose High Cost Of M&A

Financial Results Take The Shine Off Acquisitions

Executive Summary

Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.

You may also be interested in...



Merck: It’s Not Just Keytruda Driving Future Growth

The company will depend on Keytruda for growth after spinning out some franchises, but executives argued during its Q4 earnings call that there will be much more to Merck than the cancer blockbuster.

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.

Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC141636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel